The evidence for several infusions—both in acute series or as ongoing maintenance treatment—is more limited and was characterised appropriately as Amount three in the CANMAT tips. The limited knowledge replicate partly that ketamine is used off-label, and that There is certainly for that reason significantly less incentive and funding available